Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Q1 2026 results due May 14: Sana Biotechnology is scheduled to report Q1 2026 results before the market opens on Thursday, May 14, with analysts forecasting ($0.15) EPS.
• Mixed outlook and valuation: The company missed the prior quarter (reported ($0.16) vs. est. ($0.13)), analysts project about -$1 EPS for the current and next fiscal years, and the stock trades near $3.64 with a consensus target of $8.20 (average rating: Moderate Buy).

Sana Biotechnology (NASDAQ:SANA - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $3.64 on Thursday. The company has a market capitalization of $982.76 million, a price-to-earnings ratio of -3.75 and a beta of 2.17. Sana Biotechnology has a one year low of $1.60 and a one year high of $6.55. The company's fifty day moving average price is $3.37 and its two-hundred day moving average price is $4.05.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Zacks Research downgraded shares of Sana Biotechnology from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 3rd. Wedbush increased their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 14th. Morgan Stanley reissued an "overweight" rating and set a $12.00 target price on shares of Sana Biotechnology in a research report on Friday, March 13th. Weiss Ratings downgraded shares of Sana Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a "sell" rating to a "strong sell" rating in a research report on Saturday, April 25th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Sana Biotechnology has an average rating of "Moderate Buy" and a consensus target price of $8.20.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Sana Biotechnology in the third quarter valued at about $36,000. Russell Investments Group Ltd. acquired a new stake in shares of Sana Biotechnology in the third quarter valued at about $39,000. Jacobi Capital Management LLC acquired a new stake in shares of Sana Biotechnology in the fourth quarter valued at about $41,000. BNP Paribas Financial Markets grew its position in shares of Sana Biotechnology by 46.9% in the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company's stock valued at $42,000 after purchasing an additional 4,931 shares during the last quarter. Finally, Captrust Financial Advisors grew its position in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company's stock valued at $43,000 after purchasing an additional 4,807 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.